Target intelligence / Profile preview

ATP-sensitive potassium channel subunit Kir6.2–Sulfonylurea receptor 1 (Kir6.2/SUR1)

Target
Kir6.2/SUR1
Molecular classification
Ion channel, Inward rectifier potassium channel (Kir, subfamily J, member 11), ATP-binding cassette (ABC) transporter (SUR1, ABCC8), Hetero-octameric channel complex
01

Overview

The ATP-sensitive potassium channel composed of the pore-forming subunit Kir6.2 and the regulatory subunit sulfonylurea receptor 1 (SUR1) is a hetero-octameric complex that senses cellular metabolic status by coupling intracellular ATP/ADP levels to membrane excitability. Kir6.2 is a member of the inward rectifier potassium channel family, while SUR1 is an ATP-binding cassette transporter without classical transport activity, instead serving to regulate channel gating and pharmacological sensitivity. The channel is essential for regulated insulin secretion in pancreatic β-cells, linking glucose metabolism to hormone release. Mutations in either subunit disrupt glucose homeostasis and cause diseases such as diabetes or congenital hyperinsulinism. Clinically, the Kir6.2/SUR1 complex is targeted by sulfonylureas and related drugs in type 2 diabetes, while channel openers such as diazoxide are used to treat hyperinsulinemic hypoglycemia. The channel is an important therapeutic target and its molecular structure, assembly, and gating are areas of intense research, with implications for treating metabolic and neurological diseases.

Other names
KATP channel (Kir6.2/SUR1)Kir6.2–SUR1 complexATP-sensitive potassium channel (pancreatic type)KCNJ11 (Kir6.2 gene)ABCC8 (SUR1 gene)Pancreatic KATP channel
02

Mechanism of action

Sulfonylureas: Block (inhibit) the channel by binding SUR1 to promote insulin release; Meglitinides: Inhibit the channel at a binding site similar to sulfonylureas; Diazoxide: Opens the channel, hyperpolarizes cells, inhibits insulin secretion; Endogenous ATP binding to Kir6.2 closes the channel; MgADP binding to SUR1 opens the channel; Pharmacochaperoning: Small molecules stabilize Kir6.2 and SUR1 interactions, rescuing mutant channel trafficking

03

Biological functions

Regulation of insulin secretionCoupling of metabolic status to membrane excitabilityControl of cellular electrical activity in pancreatic β-cellsGlucose homeostasisModulation of neuronal excitabilityRegulation of glycolytic flux and circadian arousal
04

Disease associations

Congenital hyperinsulinism (loss-of-function mutations)Neonatal diabetes mellitus (gain-of-function mutations)Diabetes mellitus (MODY subtype, neonatal diabetes)Epilepsy (some channelopathies)Other channelopathies affecting metabolism and neurodevelopment
05

Safety considerations

Risk of hypoglycemia (sulfonylureas, in patients with activating channel mutations)Insufficient glycemic control (if channels are insensitive to sulfonylureas)Off-target cardiovascular or neurological effects (since KATP channels are expressed in other tissues)Diazoxide: Risk of hyperglycemia, fluid retention
06

Interacting drugs

Sulfonylureas (e.g., glibenclamide/glyburide, glipizide, glimepiride)

4 more in the full profile.

07

Biomarkers

Genetic mutations in KCNJ11 or ABCC8 (diagnostic for congenital hyperinsulinism, neonatal diabetes)Plasma insulin and glucose (indirect monitoring)Potential: Channel function in patient-derived cells

Beyond the preview

Go deeper on ATP-sensitive potassium channel subunit Kir6.2–Sulfonylurea receptor 1 (Kir6.2/SUR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel subunit Kir6.2–Sulfonylurea receptor 1 (Kir6.2/SUR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call